[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

December 2019 | 60 pages | ID: CCA9013D4A2FEN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019'; C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.

The report 'C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019' outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Immunology, Ophthalmology and Respiratory which include indications Gastric Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, T-Cell Lymphomas, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Allergic Asthma, Allergic Conjunctivitis, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Cervical Cancer, Chronic Urticaria Or Hives, Colon Tumor, Colorectal Cancer, Eosinophilic Esophagitis, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Hepatocellular Carcinoma (HCC), Mycosis Fungoides, Nasopharyngeal Cancer, Oral Cancer, Ovarian Cancer, Pancreatic Tumor, Rhinosinusitis, Sezary Syndrome, Solid Tumor, Spinal Cord Disorders, T-Cell Leukemia, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Tropical Spastic Paraparesis.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development
Affitech A/S
ChemoCentryx Inc
Kyowa Kirin Co Ltd
RAPT Therapeutics Inc
Tizona Therapeutics Inc
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles
AT-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCX-6239 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mogamulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CCR4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPT-193 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones
Featured News & Press Releases
Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193
Jul 08, 2019: RAPT Therapeutics announces the appointment of Emma Guttman-Yassky, M.D., Ph.D., a leading expert in the field of inflammatory skin diseases, to its scientific advisory board
Jun 03, 2019: Kyowa Kirin presents post-hoc analysis of pivotal trial for Poteligeo (mogamulizumab-kpkc)
May 13, 2019: FLX Bio highlights preclinical atopic dermatitis and asthma data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019
Dec 03, 2018: Kyowa Kirin presents additional analyses of MAVORIC trial
Nov 29, 2018: ChemoCentryx announces presentation on novel small molecule inhibitor CCX6239 at American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference
Nov 26, 2018: Kyowa Kirin announces POTELIGEO receives Marketing Authorisation in Europe for the treatment of Mycosis Fungoides and Sezary Syndrome
Nov 08, 2018: FLX Bio highlights phase 1 data for FLX475 at SITC 2018
Sep 28, 2018: Kyowa Kirin presents data at EORTC-Cutaneous Lymphoma Task Force Meeting showing significantly improved quality of life for patients With Mycosis Fungoides (MF) and Sezary Syndrome (SS) on Mogamulizumab
Sep 27, 2018: FLX Bio announces first patient dosed with FLX475, a best-in-class CCR4 inhibitor for the treatment of multiple cancers
Sep 21, 2018: Kyowa Kirin announces Mogamulizumab received positive CHMP opinion for the treatment of Mycosis Fungoides and Sezary Syndrome
Aug 29, 2018: New therapy for rare lymphoma
Aug 21, 2018: Kyowa Hakko Kirin receives the partial change approval of POTELIGEO in Japan
Aug 13, 2018: Kyowa Kirin reports positive results from MAVORIC study
Aug 10, 2018: FDA approves Kyowa Kirin’s Poteligeo to treat two lymphoma types
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Affitech A/S, H2 2019
Pipeline by ChemoCentryx Inc, H2 2019
Pipeline by Kyowa Kirin Co Ltd, H2 2019
Pipeline by RAPT Therapeutics Inc, H2 2019
Pipeline by Tizona Therapeutics Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Affitech A/S
ChemoCentryx Inc
Kyowa Kirin Co Ltd
RAPT Therapeutics Inc
Tizona Therapeutics Inc


More Publications